Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy
Federico Pessina(Humanitas University), Marta Scorsetti(Humanitas University), Stefano Tomatis(IRCCS Humanitas Research Hospital), Davide Franceschini(IRCCS Humanitas Research Hospital), Lorenza Di Guardo(Fondazione IRCCS Istituto Nazionale dei Tumori), Pierina Navarria(IRCCS Humanitas Research Hospital), Ciro Franzese(IRCCS Humanitas Research Hospital), Luca Cozzi(IRCCS Humanitas Research Hospital), Lorenzo Bello(Institute of Neurological Sciences), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), A.M. Ascolese(IRCCS Humanitas Research Hospital), Giacomo Reggiori(IRCCS Humanitas Research Hospital)
Cited by 13
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606